Total neoadjuvant therapy vs standard therapy in locally advanced rectal cancer: A single-center, real-world study in Mexico.

作者
Marytere Herrera,Jairo A. Rubio,Luis Fernando Sanchez,Rocio Pamela Martinez,C. Diaz,G. Calderillo Ruiz,Mariana Sayako Miyagui,Diana Alejandra Rubio-Delgado,Samuel Díaz,Lorena Lagarde,Erika Ruiz
出处
期刊:Journal of Clinical Oncology [Lippincott Williams & Wilkins]
卷期号:44 (2_suppl): 72-72
标识
DOI:10.1200/jco.2026.44.2_suppl.72
摘要

72 Background: Total neoadjuvant therapy (TNT) has emerged as a pivotal treatment approach for locally advanced rectal cancer (LARC). Despite its importance, there is a significant lack of comparative research examining the outcomes of chemoradiotherapy followed by surgery and adjuvant therapy (CRT) in comparison to TNT within the Mexican population. Methods: We retrospectively analyzed data of 183 patients with LARC from January 2018 to December 2022. We aimed to determine the differences in Recurrence Free Survival (RFS), Overall Survival (OS) and Pathological Complete Response by RYAN (PCR) between patients receiving TNT vs CRT though Chi square, Kaplan-Meier Meier and Cox regression methods. Results: Median age was 57 years; 55.7% of cases were male. Lower rectum was affected in 72.7%, middle in 20.2% and 7.1% in lower rectum. TNT therapy was administered in 111 cases (60.7%) an CRT in 72 cases (39.3%). Adverse Events were present in 41% in the TNT group and 33.3% in the CRT group (p 0.009). Mean RFS between CRT and TNT groups was not significant (70 months vs 63 months, p=0.323). In multivariate analyses, TNT was an independent predictor for OS (B – 1.507; HR 0.222, IC 95% 0.070-0.7; p=0.026) and PCR by RYAN was also shown to be an independent predictor of survival (p = 0.001). Conclusions: Patients who underwent TNT demonstrated enhanced OS. In our cohort, PCR by RYAN appears to serve as a surrogate marker for OS and RFS. It is imperative to carefully select patients to ensure complete therapeutic responses while avoiding overtreatment, which may result in significant toxicity. Multivariate analyses for overall survival (Cox regression). B SE Wald df Sig. Exp(B) 95.0% CI Exp(B) Inferior Superior Neoadjuvant therapy -1.507 .587 6.590 1 .010 .222 .070 .700 RYAN 20.845 3 .000 RYAN 0 -4.345 1.198 13.152 1 .000 .013 .001 .136 RYAN 1 -.570 .655 .758 1 .384 .566 .157 2.041 RYAN 2 -2.253 .643 12.260 1 .000 .105 .030 .371 Age .038 .025 2.331 1 .127 1.039 .989 1.091 Lymph node negative -1.045 .718 2.122 1 .145 .352 .086 1.435 Grade 2.941 2 .230

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
软软发布了新的文献求助10
刚刚
丘比特的应助被科研通管家采纳,获得10
刚刚
酸味yjm发布了新的文献求助10
刚刚
junjun完成签到 ,获得积分10
刚刚
lct的应助被科研通管家采纳,获得10
刚刚
000完成签到,获得积分10
1秒前
深情安青的应助被科研通管家采纳,获得10
1秒前
molihuakai的应助被科研通管家采纳,获得10
1秒前
学术雷锋的应助被Lucky采纳,获得10
1秒前
bkagyin的应助被科研通管家采纳,获得10
1秒前
白河的应助被科研通管家采纳,获得10
1秒前
所所的应助被科研通管家采纳,获得10
1秒前
Lucas的应助被科研通管家采纳,获得10
1秒前
夜暮发布了新的文献求助10
1秒前
1秒前
飘逸翠曼发布了新的文献求助10
1秒前
西瓜配夏天完成签到,获得积分10
2秒前
Qxk的应助被科研通管家采纳,获得10
2秒前
qqqqqqqq完成签到,获得积分20
2秒前
在水一方的应助被科研通管家采纳,获得10
2秒前
橘子s发布了新的文献求助10
2秒前
Owen的应助被科研通管家采纳,获得10
2秒前
冉遗的应助被科研通管家采纳,获得10
2秒前
2秒前
桐桐的应助被科研通管家采纳,获得10
2秒前
风中蜜粉完成签到,获得积分10
2秒前
JamesPei的应助被科研通管家采纳,获得10
2秒前
LuYuanxin的应助被科研通管家采纳,获得10
2秒前
3秒前
乐乐的应助被科研通管家采纳,获得10
3秒前
青年才俊发布了新的文献求助10
3秒前
脑洞疼的应助被科研通管家采纳,获得10
3秒前
天天快乐的应助被科研通管家采纳,获得10
3秒前
Jasper的应助被丰富曼青采纳,获得10
3秒前
bkagyin的应助被科研通管家采纳,获得10
3秒前
3秒前
机灵柚子的应助被科研通管家采纳,获得20
3秒前
HuiLang的应助被科研通管家采纳,获得10
3秒前
3秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
Energie-Contracting 1500
Spec 401: Standards for Jet Fuel Facility and Equipment Commissioning and Flushing at Airports, 2026.1 (Original Issue) 1000
Spec 103: Standard for Jet Fuel Quality Control at Airports, Revision 2026.1 1000
Mathematical models in hydrology 1000
Klimaschutzrecht durch den Energiesektor im Mehrebenensystem – Ein Rechtsvergleich 1000
Erzählte Gnade 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8088278
求助须知:如何正确求助?哪些是违规求助? 9501434
关于积分的说明 21425628
捐赠科研通 7659692
什么是DOI,文献DOI怎么找? 3403860
关于科研通互助平台的介绍 2532535
邀请新用户注册赠送积分活动 2442330